Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR L A 260 versus THEOCLEAR 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR L A 260 versus THEOCLEAR 100.
THEOCLEAR L.A.-260 vs THEOCLEAR-100
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing cAMP levels, and antagonizing adenosine receptors.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthmaChronic obstructive pulmonary disease (COPD)
Treatment of asthmaChronic obstructive pulmonary disease (COPD)
Theophylline (THEOCLEAR L.A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/mL.
100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/mL).
None Documented
None Documented
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In smokers, half-life is reduced by 50%; in patients with hepatic cirrhosis or heart failure, half-life is prolonged to 24-36 hours.
Hepatic via CYP1A2, CYP2E1, and CYP3A4; undergoes N-demethylation and oxidation.
Hepatic via CYP1A2 and CYP3A4; also undergoes N-demethylation and oxidation.
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Renal excretion accounts for approximately 10% of the administered dose as unchanged drug. The remainder is hepatically metabolized, with metabolites excreted renally. Biliary/fecal elimination is negligible (<5%).
Approximately 40% bound to plasma proteins, primarily albumin.
Approximately 40% bound to albumin in plasma.
Volume of distribution: 0.4-0.5 L/kg, indicating distribution into total body water. Higher Vd in neonates and patients with obesity.
Apparent volume of distribution is 0.3-0.65 L/kg, reflecting distribution throughout total body water.
Oral bioavailability: 96% to 100% for immediate-release formulations; sustained-release formulations have similar bioavailability but with prolonged absorption.
Oral immediate-release: 96-100%. Oral sustained-release: 90-100% relative to immediate-release. Rectal: 80-90%.
No specific GFR-based dose adjustment recommended; however, monitor serum levels closely in renal impairment (CrCl <30 mL/min) due to potential accumulation of metabolites.
No specific dose adjustment required for renal impairment; monitor serum levels due to altered pharmacokinetics in severe renal failure (GFR <10 mL/min).
Avoid use in Child-Pugh class C; for Child-Pugh class A or B, reduce dose by 50% and monitor serum concentrations.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: contraindicated.
Children 6 months-9 years: Starting dose 12-14 mg/kg/day orally divided every 4-6 hours (immediate-release) or every 12 hours (sustained-release). Children 9-16 years: 12-14 mg/kg/day (max 900 mg/day) divided every 6-8 hours (immediate-release) or every 12 hours (sustained-release). Adjust to serum level 5-15 mcg/mL.
Initial: 5 mg/kg/day orally divided every 6 hours; titrate based on serum levels. Maximum: 16 mg/kg/day (max 400 mg/day) for children >1 year.
Elderly patients (≥60 years): Start at 300 mg/day orally (sustained-release) in divided doses every 12 hours; titrate slowly, monitor serum levels, as clearance is reduced.
Start at lower end of dosing (e.g., 100 mg every 8-12 hours) due to decreased clearance; monitor serum concentrations closely; target 5-10 mcg/mL.
No FDA black box warning.
No FDA black box warning.
Monitor serum theophylline levels to avoid toxicity; use with caution in patients with cardiac disease, seizure disorders, hepatic impairment, or COPD exacerbation; may interact with multiple drugs altering clearance.
Monitor serum levels due to narrow therapeutic index; risk of toxicity (seizures, arrhythmias); use caution in hepatic impairment, heart failure, elderly, and with concurrent medications that alter metabolism.
Hypersensitivity to theophylline or any component; active seizure disorder not controlled by therapy.
Hypersensitivity to theophylline; porphyria.
Data Pending Review
Data Pending Review
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate theophylline's CNS stimulant effects and toxicity. Concurrent ingestion of charcoal-broiled meats may increase theophylline clearance, potentially reducing efficacy. Grapefruit juice has been reported to increase theophylline levels; limit intake. A high-protein diet may increase clearance; maintain consistent dietary habits.
High-fat meals may slow absorption of some formulations; charcoal-broiled foods and cruciferous vegetables (e.g., broccoli, cabbage) can increase theophylline clearance. Consistent dietary habits are advised to avoid fluctuations in serum levels.
Theophylline is not a major teratogen. First trimester: No increased risk of major malformations based on population data. Second and third trimesters: Use may be associated with transient neonatal toxemia (e.g., jitteriness, tachycardia, vomiting) if maternal levels are high near term. Risk of respiratory distress syndrome or neonatal apnea is theoretical only.
FDA Pregnancy Category C. First trimester: limited data suggest possible increased risk of congenital malformations; second and third trimesters: associated with fetal tachycardia, jitteriness, and respiratory distress; avoid use near term due to risk of neonatal theophylline toxicity.
Theophylline is excreted into breast milk (M/P ratio approximately 0.6-0.7). Mean milk concentration is about 60-70% of maternal plasma. Relative infant dose is ~10% of maternal weight-adjusted dose. May cause irritability or insomnia in nursing infants, especially at high maternal doses. Benefits likely outweigh risks for asthma therapy, but monitor infant for signs of theophylline toxicity.
Theophylline excreted into breast milk with infant serum levels approximately 10% of maternal; M/P ratio ~0.7. Cautious use only if benefits outweigh risks; monitor infant for irritability and poor feeding.
Pregnancy decreases theophylline clearance by 20-40% (especially third trimester). Dose may need reduction by 30-50% to maintain therapeutic levels, with close serum monitoring and adjustment every 2-4 weeks as pregnancy progresses. Smoking cessation (common in pregnancy) further reduces clearance and necessitates dose reduction.
Increased clearance in second and third trimesters may require dose increases of 30-50%; monitor levels and adjust to maintain therapeutic range; postpartum dose reduction may be needed due to clearance returning to non-pregnant levels.
Category C
Category C
Theo-24 (theophylline extended-release) has a narrow therapeutic index (5-15 mcg/mL). Monitor serum levels due to significant interindividual variability in clearance. Avoid in patients with active peptic ulcer disease or seizure disorders unless absolutely necessary. Cimetidine, ciprofloxacin, and macrolides increase levels; smoking and rifampin decrease levels. Use with caution in heart failure, hepatic impairment, and elderly due to reduced clearance. For acute exacerbations, consider short-acting beta-agonists first.
Theophylline has a narrow therapeutic index (5-15 mcg/mL). Monitor serum levels due to variable metabolism; CYP1A2 and CYP3A4 inducers (e.g., smoking, rifampin) decrease levels, while inhibitors (e.g., cimetidine, fluoroquinolones) increase toxicity. Use with caution in heart failure, hepatic impairment, and elderly. Tachyphylaxis may occur with prolonged use.
Take exactly as prescribed, do not crush or chew extended-release tablets.Avoid sudden discontinuation; may require tapering.Report symptoms of toxicity: nausea, vomiting, insomnia, jitteriness, palpitations, or seizures.Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.Discuss all medications with your doctor, especially antibiotics and heartburn drugs (cimetidine, ciprofloxacin).Do not smoke; smoking increases metabolism and may require dose adjustments.If you miss a dose, take it as soon as remembered unless close to next dose; do not double up.
Take exactly as prescribed; do not double doses.Report symptoms of toxicity: nausea, vomiting, insomnia, irritability, palpitations, seizures.Avoid smoking or sudden smoking cessation as it alters drug levels.Limit caffeine intake (coffee, tea, cola, chocolate) to avoid additive stimulant effects.Do not crush or chew extended-release tablets; swallow whole.